Mono or Combination Therapy with. Individualized Approach
|
|
- Dulcie Wilkerson
- 5 years ago
- Views:
Transcription
1 Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago drubin@uchicago.edu Nomenclature f IBD Management THEN Step Up Top Down Aggressive therapy Last ditch Hail Mary Save f last Avoid at all cost NOW Individualized care Deep remission: (clinical remission + mucosal healing) Optimization of therapy: therapeutic moniting and metabolic assessment Accelerated step care 1
2 Patients in Your Practice Patient #1: 26 yo female Crohn s ileocolitis * 3 years Steroids Thiopurine * 2 years Active symptoms me than 25% of the year Patient #2: 18 yo male Crohn s colitis and perianal Newly diagnosed, presents with diarrhea, skin tags Patient #3: 31 yo female Crohn s ileitis and jejunum Failed step care with 5-ASA, steroids, thiopurine Responded to addition of anti-tnf to thiopurine f the last 6 months Patient #4: 50 yo male UC failing 5-ASA, steroids What prevents us from using biologics earlier and maximizing combination therapy? Perception that biologics should be saved f last Perception that biologic therapies are riskier than other therapies Fear of complications of combination therapy Cost of biologics i Physician uncertainty about how to use combination therapy: the step up mindset 2
3 Mono vs. Combo Therapy of TNFinhibits in IBD: What are the issues? Artificial construct Monotherapy Combination Therapy Less expensive in sht term Patients preference? Easier f healthcare team Previous clinical trial data suppts this approach As effective as combo after failing IMM Me effective in prospective randomized trials Reduces rates of antibody fmation Results in higher blood concentrations of the biologic Similar side effect profile to monotherapy The Rationale Behind Combination Therapy in IBD There is much room f improvement in current treatment strategies (>50% failure rate in sht and long term) Multiple drugs = multiple therapeutic targets Biologic therapy + IMM reduces immunogenicity, preserves response over time Stable disease control results in disease modification 3
4 What s the Evidence f Combination Therapy? Know the Study Designs! Patients failing IMMs befe biologic therapy may not benefit from combination approach Patients who failed IMMs befe biologic therapy and are stable on combination therapy may be withdrawn from the IMMs, without loss of response to the biologic f at least two years Patients who are IMMs-naïve have efficacy benefit of combination therapy (particularly with endoscopic evidence of disease and elevated CRP) Do Concomitant Immune-modulats modulats Improve Efficacy of Infliximab in CD and UC? tients % pat tients % pat ACT I 54 wk Response IMM + IMM Ulcerative colitis ACT I 54 wk ACT I ACT II 30 wk ACT II 30 wk Patients Remission failing 54 wk IMMs Hosp befe Response biologic Remission therapy may not benefit from All p-values = NS combination approach ACCENT I 54 wk Response ACCENT I 54 wk Remission ACT II 30 wk Hosp Crohn s disease ACCENT I 54 wk Hosp ACCENT II 54 wk Response ACCENT II 54 wk Response Lichtenstein GR, Aliment Pharmacol Ther Aug;30(3): Epub 2009 Apr 21. 4
5 The Patient not Responding to Thiopurine: Consider Metabolites 6-TGn 6-MMP Possible cause Recommendation undetectable undetectable Non-adherent Understand why pt not taking med underdosed increase dose Adapted from: Dubinsky. Curr Gastroenterol Rep. 2003;5(6): The Patient not Responding to Thiopurine: Consider Metabolites 6-TGn 6-MMP Possible cause Recommendation undetectable undetectable Non-adherent Understand why pt not taking med underdosed increase dose Low (<230) Low Non-adherent Discuss adherence, undetectable underdosed increase dose Adapted from: Dubinsky. Curr Gastroenterol Rep. 2003;5(6):
6 The Patient not Responding to Thiopurine: Consider Metabolites 6-TGn 6-MMP Possible cause Recommendation undetectable undetectable Non-adherent Understand why pt not taking med underdosed increase dose Low (<230) Low Non-adherent Discuss adherence, undetectable underdosed increase dose Low (<230) High (>5700) 6-MMP shunter 1. Increase thiopurine, 2. Consider allopurinol, 3. Switch agents Adapted from: Dubinsky. Curr Gastroenterol Rep. 2003;5(6): The Patient not Responding to Thiopurine: Consider Metabolites 6-TGn 6-MMP Possible cause Recommendation undetectable undetectable Non-adherent Understand why pt not taking med underdosed increase dose Low (<230) Low Non-adherent Discuss adherence, undetectable underdosed increase dose Low (<230) High (>5700) 6-MMP shunter 1. Increase thiopurine, 2. Consider allopurinol, 3. Switch agents Therapeutic (>230-<400) High (>400) Nmal range high Primary nonresponder 1. Assess disease 2. Switch to different mechanism Adapted from: Dubinsky. Curr Gastroenterol Rep. 2003;5(6):
7 Withdrawal of Concomitant IMM in Crohn s disease while on Infliximab (failure of IMM befe IFX) No need f early rescue IFX: primary endpoint Median IFX levels, Week 8 to Week 104 combined Cum mulative survival Log Rank (Cox): 0735; Breslow: CONTINUED rough levels (μg) p<0.005 Patients who failed IMMs befe biologic therapy and are stable on combination therapy may be withdrawn from the IMMs, without loss of response to the Time (weeks) biologic f at least two years (caveat- know your patient) DISCONTINUED IFX tr 1 0 Continued Discontinued Van Asche G, et al. Gastroenterology Jun;134(7): Epub 2008 Mar 8.. Azathioprine, Infliximab Combination Therapy f Crohn s Disease (SONIC) Cticosteroid-Free Clinical Remission at Wk 26 Primary Endpoint ) Propo tion of Patients (%) p< p=0.009 p= /170 75/169 96/169 Naïve to IMM and anti-tnf TPMT nmal Median dz duration 2.4y AZA + placebo IFX + placebo IFX+ AZA Colombel, Sandbn, et al. N Engl J Med Apr 15;362(15):
8 Azathioprine, Infliximab Combination Therapy f Crohn s Disease (SONIC) Mucosal Healing at Week (%) Pro option of Patients p<0.001 p=0.023 p= /109 28/93 47/107 AZA + placebo IFX + placebo IFX+ AZA Colombel, Sandbn, et al. N Engl J Med Apr 15;362(15): Azathioprine, Infliximab Combination Therapy f Crohn s Disease (SONIC) Cticosteroid-Free Clinical Remission at Wk 50 All randomized patients (N=508)* 100 Pro option of Patients (%) p<0.001 p=0.028 p= /170 59/169 78/169 AZA + placebo IFX + placebo IFX+ AZA * Patients who did not enter the Study Extension were treated as non-responders Colombel, Sandbn, et al. N Engl J Med Apr 15;362(15):
9 COMMIT: MTX plus IFX in new onset CD patients 100 Patients in remission off steroids (%) p= p= IFX alone IFX + MTX +steroids 0 Week 14 Week 50 No difference in ITT analsyis, duration of disease <2 years, by CDAI sce No difference in infectious AEs (58.7% MTX vs 61.9% PBO) Feagan et al. Gastroenterology. 2008; 135:294 8 What about Ulcerative Colitis? 9
10 Infliximab, Azathioprine, Infliximab + Azathioprine f Moderate to Severe Ulcerative Colitis (UC SUCCESS) 100 Primary Endpoint: Steroid-Free Remission at Week 16 Percent of Patients (% %) % P=.813 P= % P= % 0 N=18 N=17 N=31 AZA (N=76) IFX (N=77) IFX+AZA (N=78) Panaccione R, DDW Abstract. Infliximab, Azathioprine, Infliximab + Azathioprine f Moderate to Severe Ulcerative Colitis (UC SUCCESS) Secondary Endpoint: Mucosal Healing at Week 16 Perc cent of Patients (%) P=.295 P=.001 P= % 55% 37% N=28 N=42 N=49 AZA (N=76) IFX (N=77) IFX+AZA (N=78) Panaccione R, DDW Abstract. 10
11 Immunogenicity of Combination Therapy Immunogenicity of TNF Antagonists with and without Concomitant Immune Modulats (IMS) Patients, % Episodic Maintenance Scheduled Maintenance IMS- IMS+ IMS- IMS+ Infliximab 1 (CD 5 mg/kg) (CD 10 mg/kg) 38% 16% 11% 8% 7% 4% Infliximab 2 (UC 5 mg/kg) 19% 2% (UC 10 mg/kg) No data 9% 4% Certolizumab 3 (PRECiSE I) 10% 4% Certolizumab 4 (PRECiSE II) 24% 8% 12% 2% Adalimumab 5 (RA, all doses) 12% 1% No data Adalimumab 6 (CLASSIC II) 4% 0% 1 Hanauer et al. Clin Gastroenterol Hepatol. 2004; 2 Sandbn et al. DDW 2007 Poster and abstract T1273; 3 Sandbn WJ, et al. N Engl J Med. 2007; 4 Schreiber S, et al. N Engl J Med. 2007; 5 Summary of Product Characteristics f adalimumab. Abbott Labaties. July 2007; 6 Sandbn WJ, et al. Gut
12 Immunogenicity of TNF Antagonists with and without Concomitant Immune Modulats (IMS) Patients, % Episodic Maintenance Scheduled Maintenance IMS- IMS+ IMS- IMS+ Infliximab 1 (CD 5 mg/kg) (CD 10 mg/kg) 38% 16% 11% 8% 7% 4% Infliximab 2 (UC 5 mg/kg) 19% 2% (UC 10 mg/kg) No data 9% 4% Certolizumab 3 (PRECiSE I) 10% 4% Certolizumab 4 (PRECiSE II) 24% 8% 12% 2% Adalimumab 5 (RA, all doses) 12% 1% No data Adalimumab 6 (CLASSIC II) 4% 0% 1 Hanauer et al. Clin Gastroenterol Hepatol. 2004; 2 Sandbn et al. DDW 2007 Poster and abstract T1273; 3 Sandbn WJ, et al. N Engl J Med. 2007; 4 Schreiber S, et al. N Engl J Med. 2007; 5 Summary of Product Characteristics f adalimumab. Abbott Labaties. July 2007; 6 Sandbn WJ, et al. Gut Safety of Combination Therapy in IBD Risks of therapy compared to risks of ineffectively treated disease 12
13 Azathioprine, Infliximab Combination Therapy f Crohn s Disease (SONIC) Adverse Events AZA + placebo IFX + placebo IFX + AZA (N=161) (N=163) (N=179) Pts with 1 AE, N (%) 144 (89.4%) 145 (89.0%) 161 (89.9%) Pts with 1 SAE, N (%) 43 (26.7%) 39 (23.9%) 27 (15.1%) Serious infections 9 (5.6%) 8 (4.9%) 7 (3.9%) >1 Infusion reactions 8 (5.0%) 22 (13.5%) 9 (5.0%) TB - 1 patient treated with infliximab and azathioprine Colon cancer - 2 patients treated with azathioprine monotherapy Death - Post colectomy, in a patient treated with azathioprine monotherapy Colombel, Sandbn, et al. N Engl J Med Apr 15;362(15): Azathioprine, Infliximab Combination Therapy f Crohn s Disease (SONIC) Adverse Events AZA + placebo IFX + placebo IFX + AZA (N=161) (N=163) (N=179) Pts with 1 AE, N (%) 144 (89.4%) 145 (89.0%) 161 (89.9%) Pts with 1 SAE, N (%) 43 (26.7%) 39 (23.9%) 27 (15.1%) Serious infections 9 (5.6%) 8 (4.9%) 7 (3.9%) >1 Infusion reactions 8 (5.0%) 22 (13.5%) 9 (5.0%) TB - 1 patient treated with infliximab and azathioprine Colon cancer - 2 patients treated with azathioprine monotherapy Death - Post colectomy, in a patient treated with azathioprine monotherapy Colombel, Sandbn, et al. N Engl J Med Apr 15;362(15):
14 Azathioprine, Infliximab Combination Therapy f Crohn s Disease (SONIC) Immunogenicity Results at Week 30* Percent of Patie ents (%) / /89 1/120 2/120 87/ /106 16/106 72/ /120 AZA +placebo IFX + placebo AZA + IFX 94 Positive Negative Inconclusive * Patients who had 1 me PK samples obtained after their first study agent administration were included in the analysis. PK data at Wk 30 was not available f 1 patient treated with AZA + placebo, 3 patients treated with IFX + placebo, and 4 patients treated with AZA + IFX. Colombel, Sandbn, et al. N Engl J Med Apr 15;362(15): Effect of trough serum infliximab concentrations on clinical outcome at >52 weeks Trough serum infliximab Detectable Undetectable Patients in remission (%) Patients with endoscopic improvement >75% (%) p< p< Patients with CRP <5 mg/dl (%) Patients with complete endoscopic remission (%) p< p= Maser et al. Clin Gastroenterol Hepatol. 2006; 4:
15 Infliximab (IFX) levels in patients taking concomitant immunosuppressives Increased IFX blood levels in IMM takers IFX levels (median + IQR) Max IFX No immunosupressives 2.42 μg/ml (1 10.8) 21 μg/ml Immunosupressives 6.45 μg/ml (3 11.6) 33.4 μg/ml AZA MTX IFX levels 6.15 μg/ml 5.65 μg/ml (median + IQR) (3 11.6) ( ) Max IFX 33.4 μg/ml 31 μg/ml p=0.065 Vermeire et al. Gut. 2007; 56: The Lymphoma Discussion NHL risk with thiopurines +/- anti-tnf Hepatosplenic T-cell lymphoma drives many decisions. Should it? Many unanswered questions Duration Dose Attenuated t risk with dose reduction withdrawal? 15
16 Proposed Approach to Mono Combo Therapy in IBD Failing Thiopurine Reassess disease reassess adherence optimize therapy (metabolites?) Add anti-tnf therapy If Response 6 months Withdraw Thiopurine? Dose reduction Unproven Proposed Approach to Mono Combo Therapy in IBD IMM/anti-TNF naive What is prognosis? High Risk Low Risk Combo IMM/TNF Step Care Male? MTX instead If deep remission If not deep remission If achieve deep remission 12 months Possible withdraw Therapy (which one?) Dose reduction Unproven 16
17 Proposed Approach to Mono Combo Therapy in IBD Anti-TNF Monotherapy Stay the course adherence to maintenance schedule Losing Response? Reassess Disease Assess drug level/antibodies l/ Add IMM? Change drug/mechanism Unproven Patients in Your Practice Patient #1: 26 yo female Crohn s ileocolitis * 3 years Steroids Thiopurine * 2 years Active symptoms me than 25% of the year Patient #2: 18 yo male Crohn s colitis and perianal Newly diagnosed, presents with diarrhea, skin tags Patient #3: 31 yo female Crohn s ileitis and jejunum Failed step care with 5-ASA, steroids, thiopurine Responded to addition of anti-tnf to thiopurine f the last 6 months Patient #4: Same as #3 but male Patient #5: 50 yo male UC failing 5-ASA, steroids 17
18 Patients in Your Practice Patient #1: 26 yo female Crohn s ileocolitis * 3 years Steroids Thiopurine * 2 years Active symptoms me than 25% of the year Proposed Approach to Mono Combo Therapy in IBD Failing Thiopurine Reassess disease reassess adherence optimize therapy (metabolites?) Add anti-tnf therapy If Response 6 months Withdraw Thiopurine? Dose reduction Unproven 18
19 Patients in Your Practice Patient #1: 26 yo female Crohn s ileocolitis * 3 years Steroids Thiopurine * 2 years Active symptoms me than 25% of the year Patient #2: 18 yo male Crohn s colitis and perianal Newly diagnosed, presents with diarrhea, skin tags Proposed Approach to Mono Combo Therapy in IBD IMM/anti-TNF naive What is prognosis? High Risk Combo IMM/TNF Male? MTX instead If achieve deep remission Possible withdraw Therapy (which one?) 12 months Dose reduction Unproven 19
20 Patients in Your Practice Patient #1: 26 yo female Crohn s ileocolitis * 3 years Steroids Thiopurine * 2 years Active symptoms me than 25% of the year Patient #2: 18 yo male Crohn s colitis and perianal Newly diagnosed, presents with diarrhea, skin tags Patient #3: 31 yo female Crohn s ileitis and jejunum Failed step care with 5-ASA, steroids, thiopurine Responded to addition of anti-tnf to thiopurine f the last 6 months Proposed Approach to Mono Combo Therapy in IBD Failing Thiopurine Reassess disease reassess adherence optimize therapy (metabolites?) Add anti-tnf therapy If Response 6 months Withdraw Thiopurine? Dose reduction Unproven 20
21 Patients in Your Practice Patient #1: 26 yo female Crohn s ileocolitis * 3 years Steroids Thiopurine * 2 years Active symptoms me than 25% of the year Patient #2: 18 yo male Crohn s colitis and perianal Newly diagnosed, presents with diarrhea, skin tags Patient #3: 31 yo female Crohn s ileitis and jejunum Failed step care with 5-ASA, steroids, thiopurine Responded to addition of anti-tnf to thiopurine f the last 6 months Patient #4: 50 yo male UC failing 5-ASA, steroids Proposed Approach to Mono Combo Therapy in IBD IMM/anti-TNF naive What is prognosis? High Risk Low Risk Combo IMM/TNF Step Care Male? MTX instead If deep remission If not deep remission If achieve deep remission Possible withdraw Therapy (which one?) 12 months Dose reduction Unproven 21
22 Individualized Approach to IBD Management Priitize: Review goals of therapy Understand prognosis of your patient- is this newly diagnosed? Optimize: Use the best treatment available f your patient Choose objective time points and endpoints of your treatments Prevent complications (screen, vaccinate) Educate about adherence and safety Maximize: Use the right dose! Minimize immunogenicity (load, combine, maintain) Monit f relapse Strategize: How long befe you reassess? How long befe you move on to another treatment? Would you adjust dosing strategy after some time? Proposed Approach to Mono Combo Therapy in IBD Failing Thiopurine IMM/anti-TNF naive Anti-TNF Monotherapy Reassess disease reassess adherence optimize therapy (metabolites?) Add anti-tnf therapy What is prognosis? High Risk Combo IMM/TNF Male? MTX instead If deep remission Low Risk Step Care If not deep remission Stay the course adherence to maintenance schedule Losing Response? Reassess Disease If Response 6 months If achieve deep remission 12 months Assess drug level/antibodies l/ Withdraw Thiopurine? Dose reduction Possible withdraw Therapy (which one?) Add IMM? Dose reduction drubin@uchicago.edu Change drug/mechanism Unproven 22
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationSevere IBD: What to Do When Anti- TNFs Don t Work?
Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Gary R. Lichtenstein, MD, FACG Professor of Medicine Director, Inflammatory Bowel Disease Program University of Pennsylvania Philadelphia, PA In my
More informationThe Refractory Crohn s Disease
The Refractory Crohn s Disease Patient David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationImmunogenicity of Biologic Agents and How to Prevent Sensitization
Immunogenicity of Biologic Agents and How to Prevent Sensitization William J. Sandborn, MD Professor and Chief, Division of Gastroenterology Director, UCSD IBD Center La Jolla, California, USA Learning
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationCROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM
CROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM Crohn's Disease Ulcerative Colitis Steroids x 2 No prior AZA/6-MP Biologic Agent AZA/6-MP STEP-UP MANAGEMENT APPROACH Advantages Patients attain remission
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationBiologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationBiologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
More informationOptimizing the effectiveness of anti-tnf therapy in paediatric IBD
Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of
More informationWithdrawal of drug therapy in patients with quiescent Crohn s disease
Withdrawal of drug therapy in patients with quiescent Crohn s disease DR. JEAN-FRÉDÉRIC COLOMBEL DIRECTOR OF THE IBD CENTER, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, USA Withdrawal of drug therapy
More informationHow to use infliximab?
How to use infliximab? Séverine Vermeire, MD, PhD Division of Gastroenterology University Hospital Gasthuisberg Leuven The how to use infliximab rules Before starting IFX: try optimizing chances for response!
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationManagement of Refractory Crohn s Disease
Management of Refractory Crohn s Disease @IBDMD David T. Rubin, MD, FACG, FASGE Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition Disclosures Consultant
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationUpdate on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationWHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY?
WHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY? Siew Ng, Professor MBBS, FRCP, (Lon, Edin), PhD (Lond), AGAF, FHKCP, FHKAM (medicine) Department of Medicine and Therapeutics Chinese University
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More information5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD
5/2/218 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD Grant support for preclinical studies: Janssen, Gusto Global, Vedanta, Artizan BALFOUR SARTOR, MD DISTINGUISHED
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Brian Feagan, MD, FACG Professor of Medicine and Epidemiology and Biostatistics Director, Robarts Clinical Trials Robarts Research Institute University
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationDisclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationAvailable Data on Pediatric Exposure Response a Clinician s Perspective
Available Data on Pediatric Exposure Response a Clinician s Perspective Marla Dubinsky, MD Professor of Pediatrics and Medicine Chief Pediatric GI and Nutrition Co-Director Susan and Leonard Feinstein
More informationTreating to Achieve a Target and Disease Monitoring in 2015: State of the Art
Treating to Achieve a Target and Disease Monitoring in 2015: State of the Art David T. Rubin, MD The Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationOptimal Use of Immunomodulators and Biologics
3/17/214 Optimal Use of Immunomodulators and Biologics Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota, U.S.A. Loftus Disclosures
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationEndpoints for Stopping Treatment in UC
Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh
More informationJoin the conversation at #GIFORUMCCFA
1 Join the conversation at #GIFORUMCCFA 2 Disclosures In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the
More informationIl ruolo degli anticorpi anti farmaco nella pratica clinica
Il ruolo degli anticorpi anti farmaco nella pratica clinica Daniela Pugliese, MD IBD Unit Complesso Integrato Columbus Gemelli Hospital Catholic University Foundation, Rome - Italy Therapeutic Drug monitoring
More informationWhen can I stop taking my medications? Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida
When can I stop taking my medications? Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Post-op low risk patient Uc de-escalation Discuss combo therapy Which one worked IBD
More informationDrug Level Monitoring in IBD. Objectives
Drug Level Monitoring in IBD Corey A. Siegel, MD, MS Director, Dartmouth-Hitchcock IBD Center Associate Professor of Medicine, Geisel School of Medicine at Dartmouth Objectives Review non-biologic drug
More informationAssociation Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Jean Frédéric Colombel, William J. Sandborn, Matthieu Allez, Jean Louis Dupas, Olivier
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationAgenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease
Agenda Predictive markers in IBD Management of ulcerative colitis Management of Crohn s disease 2 Patients With UC (%) Distribution of UC Disease Severity at Presentation 1 Fulminant disease (9%) 8 6 4
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationInflammatory Bowel Disease Drug Therapy 2016
Inflammatory Bowel Disease Drug Therapy 206 David T. Rubin, MD, FACG Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition Objectives Outline the goals of
More informationOptimizing Immunomodulators and
Optimizing Immunomodulators and Biologics i in Inflammatory Bowel Disease Sunanda Kane, MD, MSPH, FACG Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota,
More informationPersonalized Medicine. Selecting the Right First-line Biologic Agent. Gene Expression Profiles Crohn s Disease. The Right Treatment
Personalized Medicine Selecting the Right First-line Biologic Agent William Tremaine, M.D. Maxine and Jack Zarrow Professor Mayo Clinic Rochester, MN, USA The Right Treatment Pretreatment Genomic Analysis
More informationOptimizing the treatment of IBD through use of therapeutic drug monitoring
Optimizing the treatment of IBD through use of therapeutic drug monitoring Adam S. Cheifetz Director, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center Associate Professor of
More informationEmerging Therapies in IBD 2006
Overview Emerging Therapies in IBD 26 David T. Rubin, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center University of Chicago Describe the unmet needs of therapy in IBD Emerging biologic
More informationProgress in Inflammatory Bowel Disease
Progress in Inflammatory Bowel Disease Gary R Lichtenstein, MD Director, Center for IBD University of Pennsylvania School of Medicine Hospital of the University of PA Philadelphia, PA Disclosure Research,
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationMucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
More informationHighlights of DDW 2015: Crohn s disease
Highlights of DDW 2015: Crohn s disease Mark S. Silverberg, MD, PhD, FRCPC Associate Professor of Medicine, University of Toronto Staff Gastroenterologist, Mount Sinai Hospital Senior Investigator, Lunenfeld-Tanenbaum
More informationPros and Cons of Combination Therapy (Anti-TNF + IM) in Treating Children with IBD
Pros and Cons of Combination Therapy (Anti-TNF + IM) in Treating Children with IBD Jeffrey S. Hyams, MD Connecticut Children s Medical Center University of Connecticut School of Medicine Disclosures Janssen:
More informationOPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG
1C: Advances in Inflammatory Bowel Disease OPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG narrow interpretation of this presentation topic would A be a discussion of dosing
More informationRisk = probability x consequence
Explaining Risks of IBD Therapy to Parents and Patients December 4, 2009 CCFA Advances in IBD Hollywood, FL Corey A. Siegel Assistant Professor of Medicine, Dartmouth Medical School Director, Dartmouth-Hitchcock
More informationLatest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D.
Latest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D. Co-Director, IBD Center Director, Nutrition Support Service UPMC Presbyterian Hospital Division of Gastroenterology,
More informationSelection and use of the non-anti- TNF biological therapies: Who? When? How?
Selection and use of the non-anti- TNF biological therapies: Who? When? How? Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz Division of Gastroenterology The Icahn School of Medicine
More informationPersonalized Medicine: IBD
Use of Anti-TNF Antibodies and Other Serologies for Managing IBD Christopher J. Shepela, MD, MS Assistant Professor of Medicine University of Minnesota Medical Director at Digestive Disease Center at Regions
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationAnti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis
Anti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis University, 1st Department of Medicine Budapest June 13-15,
More informationAchieving Success in Ulcerative Colitis: the Role of Infliximab
Achieving Success in Ulcerative Colitis: the Role of Infliximab Dr Gill Watermeyer IBD clinic Groote Schuur Hospital 17 th August 2012 Inflammatory Bowel Disease Crohn s disease and ulcerative colitis
More information2nd Nottingham IBD Masterclass, 2017
2nd Nottingham IBD Masterclass, 217 Positioning IL12/IL23 blockade in the Crohn s disease treatment algorithm Prof James Lindsay, Consultant Gastroenterologist, Barts Health NHS Trust Professor in Inflammatory
More informationLatest Meds Approved for IBD: What are they and how do they work?
Latest Meds Approved for IBD: What are they and how do they work? JAMES LORD, MD PHD BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON MEDICAL CENTER SEPT 30, 2018 Brief history of IBD Dr. Burrill Crohn JAMA
More informationCOPYRIGHT. Inflammatory Bowel Disease What Every Clinician Needs to Know. Adam S. Cheifetz, MD. Director, Center for Inflammatory Bowel Disease
Inflammatory Bowel Disease What Every Clinician Needs to Know Adam S. Cheifetz, MD Director, Center for Inflammatory Bowel Disease Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard
More informationPositioning New Therapies
Positioning New Therapies Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker Disclosure Stephen Hanauer, MD has disclosed
More informationTherapeutic Drug Monitoring και ΙΦΝΕ το 2018
Therapeutic Drug Monitoring και ΙΦΝΕ το 2018 TDM: Ναι το χρειαζόμαστε, σε όλους και πάντοτε Κωνσταντίνος Κατσάνος Conflict of interest By means of this, the speaker confirms that he receives honoraria
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationOptimizing Therapies for Severe Ulcerative Colitis October 19, 2014
Optimizing Therapies for Severe Ulcerative Colitis October 19, 2014 Ellen J. Scherl, MD, FACP, FACG, AGAF, FASGE, NYSGEF Director Jill Roberts Center for Inflammatory Bowel Disease Jill Roberts IBD Research
More informationTreatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort
Alimentary Pharmacology and Therapeutics Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort N. Gies, K. I. Kroeker, K. Wong & R. N. Fedorak Division
More informationBiologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA
Biologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA Overview Indications and Drug Selection Contraindications
More informationPredicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab.
Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab. Dr Peter Irving Guy s and St Thomas Hospital, London King s College London Response to vedolizumab
More informationThe Best of IBD at UEGW (Crohn s)
The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best
More informationAli Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
More informationNew treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital
New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.
More informationLatest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker
More informationTo help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture,
To help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture, click Options in the Message Bar, and then click Enable
More informationLessons to learn from Crohn's disease clinical trials: implications for ulcerative colitis
Lessons to learn from Crohn's disease clinical trials: implications for ulcerative colitis Aránzazu Jáuregui Amézaga, Elena Ricart, Julián Panés Department of Gastroenterology, Hospital Clínic de Barcelona,
More informationTherapy for Inflammatory Bowel Disease
Therapy for Inflammatory Bowel Disease Jonathan P. Terdiman, MD Professor of Clinical Medicine Clinical Director, Center for Colitis and Crohn s Disease University of California San Francisco, CA UC: Current
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Sunanda Kane, MD, FACG Professor of Medicine Department of Gastroenterology and Hepatology Mayo Clinic Rochester, MN In my lecture today, I will be
More informationAdverse Events From Biologic Agents in IBD
Adverse Events From Biologic Agents in IBD David A. Schwartz, MD, FACG Director, Inflammatory Bowel Disease Center Professor of Medicine Vanderbilt University Medical Center Case Page 1 of 24 28 yo with
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationEmerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD
Emerging g therapies for IBD: A practical approach to positioning Stephen B. Hanauer, MD Sequential Therapies for IBD Disease Severity at Presentation Severe Anti-TNF +/IS Cyclosporine (UC) Colectomy (UC)
More informationPerianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic
Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification
More informationΑπό τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών. Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων
Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων Conflict of interest By means of this, the speaker confirms that
More informationCrohn s
Crohn s Disease David T. Rubin, MD, AGAF Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology, and Nutrition Co-Director, Digestive Diseases Center @IBDMD Disclosures
More informationCrohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?
Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation? Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic
More informationPrimary & Secondary Care Inflammatory Bowel Disease Pathway February 2018
South East London Area Prescribing Committee: Primary & Secondary Care Inflammatory Bowel Disease Pathway February 2018 Developed by: South East London IBD Pathway Development Group Approved: February
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Francis A. Farraye, MD, MSc, FACG Professor of Medicine Clinical Director, Section of Gastroenterology Boston University School of Medicine Boston,
More informationIBD Case Studies. David Rowbotham. Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital
IBD Case Studies David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust
More informationUlcerative Colitis: Refining our Management and Incorporating Newer Concepts
Ulcerative Colitis: Refining our Management and Incorporating Newer Concepts Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz The Mt. Sinai School of Medicine Refining our Management
More informationManaging Complications of IBD and Its Therapies David T. Rubin, MD, AGAF
Managing Complications of IBD and Its Therapies David T. Rubin, MD, AGAF Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition University of Chicago Medicine
More informationCommunicating with the IBD Patient: How to convey risks and benefits
Communicating with the IBD Patient: How to convey risks and benefits October 30, 2011 ACG Postgraduate Course National Harbor, Maryland Corey A. Siegel, MD Assistant Professor of Medicine Dartmouth Medical
More informationMild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested. Philippe Marteau, Paris, France
Mild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested Philippe Marteau, Paris, France Sequential vs combined treatments When should one switch? Sequential vs combined treatments
More information